iScience, Volume 25

Supplemental information

Premise and peril of Wnt signaling activation through GSK-3 β inhibition

Samuel M. Law and Jie J. Zheng

		CHIR (0.1)	CHIR (10)	AR (10)	TWS (3.3)	TWS (10)
PC3	Up	BIN1 LARGE	CIAPINI EXOC3 GNAII MLF1 RDH11 SENP6 ST7 TM9SF3 TMEM194A	CD9 CPE FAM69A HLA-DQA1 IGFBP5 IGL@ PCP4 PLA2G4A SELENBP1 TMEM158	<u>PSPH</u>	AIF1 HIST1H2AC MMP1 SERPINE1
	Down	KLF5 SEPT7 ZNF148	ADO EIF1AY RAB30	AGR2 ANKRD10 CDH2 EIF5 FOLR1 HOXC6 HSPA1A POLD4 RPL37A SCD	ACLY CYP1B1 DFFB ZDHHC6	ADO ALDH1A3 C16ORF59 C22ORF29 CYP1B1 DFFB FOSL1 HNRNPU IER3 IGFBP3 IIL8 MAFF MMP11 MYC PDLIM1 PLEK SERPINE1 TIPARP

Supplemental Table 1: The genes documented in the L1000 database (Keenan *et al.*, 2018) are affected by three GSK-3 β inhibitors, CHIR: CHIR-99021, AR: AR-A014418, and TWS: TWS-119, in PC3 cells. Underlined genes represent those that exhibit altered gene expression in both PC3 and HA1E (supplemental table 2) cells. Although PC3 and HA1E cells differ significantly in embryonic origin, a large portion of the affected genes shared between these two cell lines exhibit overlap when treated with these three GSK-3 β inhibitors. The double-underlined and red-font genes exhibit altered gene expression in both PC3 and HA1E cell lines and are altered by at least one other perturbagen (CHIR-99021, AR-A014418, TWS-119). The concentrations (in μ M) of the compounds used to treat the cells are indicated in the parentheses.

		CHIR (10)	AR (10)	TWS (1.1)	TWS (3.3)	TWS (10)
HA1E	Up	CHIR (10) CIAPINI EIF3G EPAG GNAII MAPKIIPIL MLF1 PCDH11Y RDH11 SENP6 SNX13 ST7 TM9SF3	AR (10) ATF3 CPE EMP1 GPNMB HIST1H1C HLA-DQA1 IGFBP5 LAPTM5 MMP9 PCP4 PLA2G4A RGS1 S100A8 SPARCL1 TMEM158	AIF1 ALDOB ATP5S RNF10	ALDOB ATP5S PSPH RNF10	CFB CXCR4 HIST1H2AC PSPH RNF10 S100A8 ZMYND8
	Down	CRADD DFFB EIF1AY KLF5 LPAR1 PPP2R5D RSG1 SLC16A3 TRIM23 VPS13A XPO6	CDH2 EIF5 GAS1 NIPSNAP1 POLD4 PTGIS SCD SLC2A6 TM4SF1 TMEM5 TNFAIP2 TSPAN8	MMP1 PLEK	ATP9B COPS6 CXCR4 EIF4E2 HNRNPU MMP1 MRPL18 PDLIM1 RAB30 SQRDL TRIOBP UBE3B	ADO ALDH1A3 C16ORF59 C22ORF29 COPS6 CXCR4 CYP1B1 DFFB DUSP4 FOSL1 HNRNPU IER3 IGFBP3 IL8 LDLR MAFF MANBA MMP1 MMP11 MRPL18 MYC PLEK RAB30 SERPINE1 SQRDL TIPARP UBE3B ZDHHC6

Supplemental Table 2: The genes documented in the L1000 database (Keenan *et al.*, 2018) are affected by three GSK-3β inhibitors, CHIR: CHIR-99021, AR: AR-A014418, and TWS: TWS-119, in HA1E cells. Underlined genes represent those that exhibit altered gene expression in both HA1E and PC3 (supplemental table 1) cells. Although PC3 and HA1E cells differ significantly in embryonic origin, a

large portion of the affected genes shared between these two cell lines exhibit overlap when treated with these three GSK-3 β inhibitors. The double-underlined and red-font genes exhibit altered gene expression in both PC3 and HA1E cell lines and are altered by at least one other perturbagen (CHIR-99021, AR-A014418, TWS-119). The concentrations (in μ M) of the compounds used to treat the cells are indicated in the parentheses.